Your Search Results

How to treat aortic regurgitation

22 May 2026 – From EuroPCR 2026

Explore cutting-edge transcatheter approaches for aortic regurgitation, including first-in-human ATLAS technique, management in LVAD patients, and off-label Myval use. This session reviews clinical challenges and innovative solutions in aortic valve interventions, offering valuable insights from complex procedural experiences.

Left main complications - Part 3

21 May 2026 – From EuroPCR 2026

This session reviews complex complications encountered in left main coronary interventions. It covers causes and management of acute left main occlusion, critical stenosis of coronary buttons, retrieval techniques for ostial stents, and strategies for managing challenging PCI scenarios that may precipitate or resolve catastrophic events.

Left main PCI, what is known and what is new

21 May 2026 – From EuroPCR 2026

This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...

Left main PCI: predictions of risk and long-term clinical outcome

22 May 2026 – From EuroPCR 2026

This session focuses on risk prediction and long-term outcomes following left main percutaneous coronary intervention (PCI). It covers biomarkers like NT-proBNP, hemodynamic predictors, and the impact of comorbidities such as diabetes and chronic kidney disease on patient prognosis over a ten-year follow-up.

Multivessel disease or left main disease

22 May 2026 – From EuroPCR 2026

This session explores revascularisation strategies for patients with multivessel or left main coronary artery disease. It emphasizes the role of intravascular physiology and imaging in guiding treatment decisions and highlights procedural factors that contribute to improved long-term clinical outcomes, supported by complex case discussions.

TAVI interventions for all? From congenital bicuspid valve towards valve-in-valve challenging cases

21 May 2026 – From EuroPCR 2026

This session delves into the complexities of TAVI interventions across diverse challenging cases, including congenital bicuspid valves and valve-in-valve scenarios. It emphasizes complication prevention, decision-making for the Unicorn technique, and the critical role of pre-procedural imaging, illustrated through detailed case studies from Estonia, the Netherlands, and...

When atrial septal closure gets complex

21 May 2026 – From EuroPCR 2026

This session explores the complexities that arise when atrial septal closure procedures become challenging. It covers hybrid retrieval techniques for occluder devices, management of device-related complications mimicking infection, resolution of uncommon complications, and case studies including cryptogenic stroke management in athletes, highlighting procedural intricacies and solutions.

STEMI management around the world

21 May 2026 – From EuroPCR 2026

This session presents a global perspective on STEMI management, addressing strategies to reduce reperfusion delays through nurse-integrated pathways and comparing intracoronary versus intravenous Tirofiban use during primary PCI. It includes epidemiological insights from Rwanda and Egypt, evaluates thrombo-aspiration practices in Sub-Saharan Africa, and examines outcomes in...

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Author

Mirvat Alasnag

OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?

02 Sep 2024

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Author

Luis Ortega-Paz

Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials

14 Nov 2021

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Author

Vijay Kunadian

ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines

29 Aug 2021

There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...

Author

Mirvat Alasnag

Evidence base: current data on TAVI durability and long-term outcomes

18 Jun 2026

This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.